Boulevard Bio Launches with $65 Million to Advance Precision Immunology Pipeline
Biotechnology company Boulevard Bio has secured $65 million in funding from Deerfield Management. The company aims to advance its precision immunology pipeline.
Boulevard Bio, a new biotechnology company, has announced the closing of a $65 million funding round led by Deerfield Management. The capital will be used to advance the company's pipeline of precision immunology therapies.
The company is focused on developing treatments for autoimmune diseases, aiming to create novel therapies by precisely targeting specific immune cells. The investment from Deerfield Management will support Boulevard Bio's early-stage research and development efforts.
Boulevard Bio's founding team includes notable experts such as Professor Georg Schett, MD, an expert in rheumatology and immunology. Frank Nestle, MD, a Partner at Deerfield Management and CEO of Deerfield Discovery and Development (3DC), also serves as a scientific co-founder and board member.
The company seeks to leverage advancements in precision immunology to develop significantly improved treatments for patients suffering from chronic autoimmune conditions. Boulevard Bio intends to bring new, more effective therapeutic options to market.